UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Subtyping of triple‐negative breast cancer: Implications for therapy

Cancer, 2015-01, Vol.121 (1), p.8-16

2015

Volltextzugriff (PDF)

TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes

Journal of clinical oncology, 2020-12, Vol.38 (36), p.4274-4282

2020

Volltextzugriff (PDF)

Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer

Frontiers in oncology, 2018-08, Vol.8, p.308-308

2018

Volltextzugriff (PDF)

The bone-muscle connection in breast cancer: implications and therapeutic strategies to preserve musculoskeletal health

Breast cancer research : BCR, 2022-11, Vol.24 (1), p.84-84, Article 84

2022

Volltextzugriff (PDF)

Impact of Body Mass Index on Presence of ctDNA and Disease Recurrence after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Analysis from BRE12-158

Clinical cancer research, 2021-02, Vol.27 (4), p.1195-1199

2021

Volltextzugriff (PDF)

Exercise as part of survivorship care in metastatic breast cancer: protocol for the randomized EMBody trial

BMC cancer, 2024-09, Vol.24 (1), p.1137-9, Article 1137

2024

Volltextzugriff (PDF)

Impact of African ancestry on the relationship between body mass index and survival in an early‐stage breast cancer trial (ECOG‐ACRIN E5103)

Cancer, 2022-06, Vol.128 (11), p.2174-2181

2022

Volltextzugriff (PDF)

Reply to K. Nozawa et al

Journal of clinical oncology, 2022-06, Vol.40 (17), p.1963-1964

2022

Volltextzugriff (PDF)

Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial

JAMA oncology, 2020-09, Vol.6 (9), p.1410

2020

Volltextzugriff (PDF)

Molecular and clinical effects of aromatase inhibitor therapy on skeletal muscle function in early-stage breast cancer

Scientific reports, 2024-01, Vol.14 (1), p.1029-1029, Article 1029

2024

Volltextzugriff (PDF)

Landmark trials in the medical oncology management of metastatic breast cancer

Seminars in oncology, 2021-06, Vol.48 (3), p.246-258

2021

Volltextzugriff (PDF)

Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer

Clinical cancer research, 2022-08, Vol.28 (15), p.3235-3241

2022

Volltextzugriff (PDF)

Racial disparities in cascade testing for cancer predisposition genes

Preventive medicine, 2023-07, Vol.172, p.107539-107539, Article 107539

2023

Volltextzugriff (PDF)

Physical activity and risk of benign proliferative epithelial disorders of the breast, in the Women’s Health Initiative

International journal of epidemiology, 2022-01, Vol.50 (6), p.1948-1958

2022

Volltextzugriff (PDF)

Impact of Muscle Measures on Outcome in Patients Receiving Endocrine Therapy for Metastatic Breast Cancer: Analysis of ECOG-ACRIN E2112

Journal of the National Comprehensive Cancer Network, 2023-09, Vol.21 (9), p.915-923.e1

2023

Volltextzugriff (PDF)

Current HER2 Testing Recommendations and Clinical Relevance as a Predictor of Response to Targeted Therapy

Clinical breast cancer, 2015-06, Vol.15 (3), p.171-180

2015

Volltextzugriff (PDF)

ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer

Journal of clinical oncology, 2024-08, Vol.42 (24), p.2899-2907

2024

Volltextzugriff (PDF)

Discerning the impact of ctDNA detection on patient decision-making in early-stage breast cancer

NPJ breast cancer, 2024-10, Vol.10 (1), p.89, Article 89

2024

Volltextzugriff (PDF)

A Personalized, Dynamic Physical Activity Intervention Is Feasible and Improves Energetic Capacity, Energy Expenditure, and Quality of Life in Breast Cancer Survivors

Frontiers in oncology, 2021-04, Vol.11, p.626180-626180

2021

Volltextzugriff (PDF)

Imaging modalities for measuring body composition in patients with cancer: opportunities and challenges

Journal of the National Cancer Institute. Monographs, 2023-05, Vol.2023 (61), p.56-67

2023

Volltextzugriff (PDF)

Proton Pump Inhibitor Use and Obesity-Associated Cancer in the Women's Health Initiative

Nutrition and cancer, 2023, Vol.75 (1), p.265-275

2023

Volltextzugriff (PDF)

Impact of primary breast cancer therapy on energetic capacity and body composition

Breast cancer research and treatment, 2018-11, Vol.172 (2), p.445-452

2018

Volltextzugriff (PDF)

Energy balance in advanced breast cancer: extending beyond the curative setting

Clinical advances in hematology & oncology, 2022-12, Vol.20 (12), p.727-733

2022

Volltextzugriff (PDF)

Evaluating the Clinical Utility of Circulating Tumor Cells in Metastatic Breast Cancer-Is Not Worse Good Enough?

JAMA oncology, 2021-01, Vol.7 (1), p.30

2021

Volltextzugriff (PDF)

1 – 25 von 81

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(76)
Mit Volltextzugriff
(65)

Publikationsform

Artikel
(79)
Buchkapitel
(2)

Sprache

Englisch
(81)

Erscheinungsjahr

n.n

Thema

Science & Technology
(35)
Life Sciences & Biomedicine
(34)
Humans
(30)
Oncology
(30)
Female
(24)
Breast Cancer
(22)
Middle Aged
(14)
Adult
(13)
Aged
(10)
Breast Neoplasms - Pathology
(7)
Chemotherapy
(7)
Triple Negative Breast Neoplasms - Drug Therapy
(7)
Breast Neoplasms - Drug Therapy
(6)
Cancer
(6)
Cancer Therapies
(6)
Risk Factors
(6)
Triple Negative Breast Neoplasms - Genetics
(6)
Breast Neoplasms - Genetics
(5)
Care And Treatment
(5)
Clinical Trials
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Subtyping of triple‐negative breast cancer: Implications for therapy

TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes

Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer

The bone-muscle connection in breast cancer: implications and therapeutic strategies to preserve musculoskeletal health

Impact of Body Mass Index on Presence of ctDNA and Disease Recurrence after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Analysis from BRE12-158

Exercise as part of survivorship care in metastatic breast cancer: protocol for the randomized EMBody trial

Impact of African ancestry on the relationship between body mass index and survival in an early‐stage breast cancer trial (ECOG‐ACRIN E5103)

Reply to K. Nozawa et al

Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial

Molecular and clinical effects of aromatase inhibitor therapy on skeletal muscle function in early-stage breast cancer

Landmark trials in the medical oncology management of metastatic breast cancer

Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer

Racial disparities in cascade testing for cancer predisposition genes

Physical activity and risk of benign proliferative epithelial disorders of the breast, in the Women’s Health Initiative

Impact of Muscle Measures on Outcome in Patients Receiving Endocrine Therapy for Metastatic Breast Cancer: Analysis of ECOG-ACRIN E2112

Current HER2 Testing Recommendations and Clinical Relevance as a Predictor of Response to Targeted Therapy

ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer

Discerning the impact of ctDNA detection on patient decision-making in early-stage breast cancer

BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer

A Personalized, Dynamic Physical Activity Intervention Is Feasible and Improves Energetic Capacity, Energy Expenditure, and Quality of Life in Breast Cancer Survivors

Imaging modalities for measuring body composition in patients with cancer: opportunities and challenges

Proton Pump Inhibitor Use and Obesity-Associated Cancer in the Women's Health Initiative

Impact of primary breast cancer therapy on energetic capacity and body composition

Energy balance in advanced breast cancer: extending beyond the curative setting

Evaluating the Clinical Utility of Circulating Tumor Cells in Metastatic Breast Cancer-Is Not Worse Good Enough?

Suchergebnisse filtern